NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations...
Archive for category: News
Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosis, News
NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke Neuroscience, a medical device company developing and commercializing technologies...
Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD Patients, News
Allied Corp. (OTC Pink: ALID) (“Allied”), an international medical cannabis production company focused on creating and providing targeted cannabinoid...
NEW YORK CITY, NY, USA, September 10, 2019 /EINPresswire.com/ — Evoke Neuroscience has been awarded a working contract by...
Evoke Neuroscience announces it has been selected to present to the attendees of this year’s ROTH Capital Conference on...
NEW YORK, NEW YORK, USA, November 8, 2018 /EINPresswire.com/ – Evoke Neuroscience won the popular vote by attendees and...
NEW YORK, NY, USA, October 11, 2018 /EINPresswire.com/ – Evoke Neuroscience announces it has been selected to present to...
New York, NY, March 29, 2018 – Evoke Neuroscience has been awarded a group purchasing agreement as a breakthrough...
Evoke Neuroscience, Inc. is pleased to announce the award of a Veterans Health Administration Contract for the eVox® System....
Schedule a Free eVox Clinical Demonstration in Your Office
Evoke Neuroscience was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easy-to-use products. Physicians use the eVox® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.
Artificial Intelligence Expert Neil Sahota Joins Evoke Neuroscience Executive Advisory BoardMay 7, 2020
NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke N...
Evoke Neuroscience aims to develop Artificial Intelligence biomarker for Alzheimer’s disease diagnosisNovember 8, 2019
NEW YORK, NY, USA, November 8, 2019 /EINPresswire.com/ — Evoke N...
Allied : Signs Letter of Intent with Evoke Neurosciences to Partner on the Analysis and Treatment of PTSD PatientsSeptember 18, 2019
Allied Corp. (OTC Pink: ALID) (“Allied”), an international...
Email – firstname.lastname@example.org
Phone – 917.261.6096
(Monday-Friday: 9:30 a.m. – 5:30 p.m. ET)
Evoke Neuroscience – NY
1115 Broadway 12th Floor
New York, NY 10010
Evoke Neuroscience – CA
4041 MacArthur Blvd., 4th floor
Newport Beach, CA 92660
© Copyright 2021 — Evoke Neuroscience, Inc.
The eVox system is a Class II medical device that has received Section 510(K) clearance from the FDA. It is intended for the acquisition, display, and storage, of electrical activity of a patient’s brain including electroencephalograph (EEG) and event-related potentials (ERP) obtained by placing two or more electrodes on the head to aid in diagnosis.